Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Coeptis Therapeutics Holdings Inc (COEPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: COEPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.12% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.59 | 52 Weeks Range 0.00 - 0.05 | Updated Date 02/25/2025 |
52 Weeks Range 0.00 - 0.05 | Updated Date 02/25/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -245.55% | Return on Equity (TTM) -1449.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 12704886 |
Shares Outstanding - | Shares Floating 12704886 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Coeptis Therapeutics Holdings Inc
Company Overview
History and Background
Coeptis Therapeutics Holdings Inc. is a biopharmaceutical company focused on developing innovative therapies. Founded with a mission to address unmet medical needs, Coeptis has evolved through strategic acquisitions and partnerships.
Core Business Areas
- Oncology: Developing targeted therapies and diagnostics for various cancer types, including cell therapies and immunotherapies.
- Drug Development and Commercialization: Acquiring, developing, and commercializing pharmaceutical products to address therapeutic areas with unmet needs.
Leadership and Structure
The company's leadership team comprises experienced professionals in the pharmaceutical and biotech industries. The organizational structure includes departments for research and development, clinical trials, and commercial operations.
Top Products and Market Share
Key Offerings
- Consensus Vaccine: A universal pan-coronavirus and pan-influenza vaccine candidate aimed at providing broad protection against future variants and strains. Market share is currently not significant as the vaccine is in development. Competitors include Pfizer (PFE), Moderna (MRNA), and Novavax (NVAX).
- CD38-GEARS: A novel T cell engager technology designed to redirect the body's immune system to fight cancer cells expressing the CD38 target. Market share is currently not significant as the therapy is in development. Competitors include Johnson & Johnson (JNJ) with Darzalex.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. There is significant innovation in oncology, cell therapies, and vaccine development.
Positioning
Coeptis Therapeutics Holdings Inc aims to carve a niche in the market by developing innovative therapies and strategic partnerships. The company is positioned as a specialized biopharmaceutical company focused on unmet medical needs.
Total Addressable Market (TAM)
The TAM for oncology and vaccine markets is estimated to be in the hundreds of billions of dollars. Coeptis aims to capture a portion of this TAM with its innovative therapies, starting from the early stage clinical trials.
Upturn SWOT Analysis
Strengths
- Innovative technology platforms
- Experienced leadership team
- Focus on unmet medical needs
- Strategic partnerships and acquisitions
Weaknesses
- Limited financial resources
- Early-stage development pipeline
- Dependence on strategic partnerships
- Small market capitalization
Opportunities
- Expanding product pipeline through acquisitions
- Securing strategic partnerships with larger pharmaceutical companies
- Gaining regulatory approvals for lead product candidates
- Growing market for oncology and vaccine therapies
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Funding challenges
- Intellectual property risks
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- JNJ
- NVAX
Competitive Landscape
Coeptis Therapeutics Holdings Inc faces significant competition from larger, well-established pharmaceutical companies. Its competitive advantage lies in its innovative technology platforms and focus on unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been marked by strategic acquisitions and partnerships.
Future Projections: Future growth is dependent on clinical trial successes and regulatory approvals. Analyst estimates are required for an accurate forecast.
Recent Initiatives: Recent initiatives include the advancement of lead product candidates into clinical trials and the exploration of strategic partnerships.
Summary
Coeptis Therapeutics Holdings Inc. is an early-stage biopharmaceutical company with innovative technology. Its focus on addressing unmet medical needs through strategic acquisitions and partnerships shows promise. Limited financial resources and an early-stage development pipeline represent risks. The company must navigate regulatory hurdles and clinical trial results effectively to realize its potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- Public Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Coeptis Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters Wexford, PA, United States | ||
IPO Launch date 2020-12-17 | Co-Founder, Chairman, CEO & Pres Mr. David Mehalick | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://coeptispharma.com |
Full time employees 4 | Website https://coeptispharma.com | ||
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.